CIRBP and urinary bladder cancer: However, recent studies found that CIRBP was overexpressed in prostate cancer (Zeng et al., 2009), liver cancer (Lee et al., 2015), breast cancer (Guo et al., 2010), and bladder cancer (Lu et al., 2018) and was involved in upregulating telomerase activity, promoting proliferation, inhibiting apoptosis, and promoting epithelial-mesenchymal transition (EMT) (Zhang et al., 2016).